9 - New Antimicrobials in the Pipeline Part 1

Thursday, October 12, 2023

8:00 AM – 9:00 AM US ET

Location: 104 ABC

CE: No CE Credit Offered

All relevant financial disclosures have been mitigated.

Moderator(s)

CC

Cornelius Clancy, MD

University of Pittsburgh
Pittsburgh, PA, United States
Lisa Dumkow, Pharm D., BCIDP (she/her/hers)

Infectious Disease Clinical Pharmacist
Trinity Health Grand Rapids
Grand Rapids, MI, United States

Disclosure(s):

Cornelius J. Clancy, MD: Merck and Co: Grant/Research Support (Ongoing); Qpex: Advisor/Consultant (Ongoing); Shionogi: Advisor/Consultant (Ongoing); T2Biosystems: Advisor/Consultant (Ongoing); VenatoRx: Advisor/Consultant (Ongoing)

Lisa E. Dumkow, Pharm D., BCIDP: No financial relationships to disclose

Presentations:

8:00 AM – 8:12 AM US ET

Novel DNA pol IIIC Inhibitors for Gram-positive Bacterial Infections
Speaker: Robert J. DeLuccia – Acurx Pharmaceuticals, Inc.
8:12 AM – 8:24 AM US ET

MAT2203, A Novel Oral Delivery of Amphotericin B (AMB), in Phase 3 Development for the Treatment of Invasive Fungal Infections (Matinas BioPharma)
Speaker: Theresa Matkovits, PhD – Matinas BioPharma Holdings, Inc.
8:24 AM – 8:36 AM US ET

posoleucel (allogeneic, off-the-shelf, multivirus specific T cells designed to target AdV, BKV, CMV, EBV, HHV-6 and JCV) / AlloVir
Speaker: Richard Riese – AlloVir
8:36 AM – 8:48 AM US ET

Xeruborbactam IV and Oral
Speaker: Olga Lomovskaya, PhD – Qpex Biopharma, The Wholly Owned Subsidiary of Shionogi
8:48 AM – 9:00 AM US ET

Epetraborole
Speaker: Paul B. Eckburg, MD (he/him/his) – AN2 Therapeutics